NO316155B1 - Forbedret vevslim fremstilt ved anvendelse av kryopresipitat, fremgangsmåtefor fremstilling derav, samt anvendelse av en mengde avproteaseinhibitor - Google Patents
Forbedret vevslim fremstilt ved anvendelse av kryopresipitat, fremgangsmåtefor fremstilling derav, samt anvendelse av en mengde avproteaseinhibitor Download PDFInfo
- Publication number
- NO316155B1 NO316155B1 NO19923737A NO923737A NO316155B1 NO 316155 B1 NO316155 B1 NO 316155B1 NO 19923737 A NO19923737 A NO 19923737A NO 923737 A NO923737 A NO 923737A NO 316155 B1 NO316155 B1 NO 316155B1
- Authority
- NO
- Norway
- Prior art keywords
- component
- tissue
- aprotinin
- cryoprecipitate
- kiu
- Prior art date
Links
- 239000003106 tissue adhesive Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title description 10
- 239000003112 inhibitor Substances 0.000 title description 3
- 108010039627 Aprotinin Proteins 0.000 claims abstract description 22
- 108010027612 Batroxobin Proteins 0.000 claims abstract description 22
- 108091005804 Peptidases Proteins 0.000 claims abstract description 22
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 22
- 229960004405 aprotinin Drugs 0.000 claims abstract description 21
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 19
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 19
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 19
- 102000035195 Peptidases Human genes 0.000 claims abstract description 14
- 239000004365 Protease Substances 0.000 claims abstract description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 229960002210 batroxobin Drugs 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims abstract description 4
- 239000002435 venom Substances 0.000 claims abstract description 3
- 210000001048 venom Anatomy 0.000 claims abstract description 3
- 231100000611 venom Toxicity 0.000 claims abstract description 3
- 229960004072 thrombin Drugs 0.000 claims description 38
- 108090000190 Thrombin Proteins 0.000 claims description 37
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 15
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 12
- 239000003998 snake venom Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 7
- 108010073385 Fibrin Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000010257 thawing Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 108010071289 Factor XIII Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 229940012444 factor xiii Drugs 0.000 claims description 5
- 241000271506 Bothrops Species 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims 5
- 241000271897 Viperidae Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 239000001110 calcium chloride Substances 0.000 description 12
- 229910001628 calcium chloride Inorganic materials 0.000 description 12
- 235000011148 calcium chloride Nutrition 0.000 description 12
- 239000003292 glue Substances 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 208000034158 bleeding Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108010054218 Factor VIII Proteins 0.000 description 4
- 102000001690 Factor VIII Human genes 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229960000301 factor viii Drugs 0.000 description 4
- 208000031169 hemorrhagic disease Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 108010027490 Antagosan Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical class NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 1
- 230000000058 esterolytic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 fibrnectin Proteins 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Materials For Medical Uses (AREA)
- Pyrane Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Packages (AREA)
- Vehicle Body Suspensions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1991/001850 WO1993005822A1 (en) | 1991-09-27 | 1991-09-27 | Tissue glue prepared by using cryoprecipitate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO923737D0 NO923737D0 (no) | 1992-09-25 |
| NO923737L NO923737L (no) | 1993-03-29 |
| NO316155B1 true NO316155B1 (no) | 2003-12-22 |
Family
ID=8165612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19923737A NO316155B1 (no) | 1991-09-27 | 1992-09-25 | Forbedret vevslim fremstilt ved anvendelse av kryopresipitat, fremgangsmåtefor fremstilling derav, samt anvendelse av en mengde avproteaseinhibitor |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JP2668762B2 (pt) |
| AT (1) | ATE200631T1 (pt) |
| AU (1) | AU648198B2 (pt) |
| BR (1) | BR9203763A (pt) |
| CA (1) | CA2079077C (pt) |
| CZ (1) | CZ280540B6 (pt) |
| DE (1) | DE69231791T2 (pt) |
| ES (1) | ES2155437T3 (pt) |
| FI (1) | FI924306A (pt) |
| HU (2) | HUT67051A (pt) |
| IL (1) | IL103118A (pt) |
| NO (1) | NO316155B1 (pt) |
| SK (1) | SK294292A3 (pt) |
| WO (1) | WO1993005822A1 (pt) |
| ZA (1) | ZA927360B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69229272T2 (de) * | 1991-09-05 | 2000-02-03 | Baxter International Inc., Deerfield | Topischer fibrinogenkomplex |
| ITMI20021917A1 (it) * | 2002-09-10 | 2004-03-11 | New Dawn Consultores E Servicos L Da | Attivatore per la formazione di gel piastrinico, gel di plasma povero di piastrine o gel di plasma ricco di piastrine. |
| EP2011524A1 (en) | 2007-07-02 | 2009-01-07 | Omrix Biopharmaceuticals Ltd. | Fibrin glue with a visualization agent |
| EP2034010A1 (en) | 2007-08-30 | 2009-03-11 | Omrix Biopharmaceuticals Ltd. | Compositions suitable for repair and/or treatment of injured spinal tissue |
| WO2010032246A2 (en) | 2008-09-22 | 2010-03-25 | Omrix Biopharmaceuticals Ltd. | Implantable device comprising a substrate pre-coated with stabilized fibrin |
| ES2513516T3 (es) | 2010-01-28 | 2014-10-27 | Omrix Biopharmaceuticals Ltd. | Método para un sellado con fibrina mejorado |
| IL213864A0 (en) | 2011-06-30 | 2011-08-31 | Omrix Biopharmaceuticals Ltd | Method for removing a lytic enzyme from a heterogeneous mixture |
| US10130346B2 (en) | 2012-07-24 | 2018-11-20 | Omrix Biopharmaceuticals Ltd. | Device and method for the application of a curable fluid composition to a bodily organ |
| US10849605B2 (en) | 2012-12-30 | 2020-12-01 | Omrix Biopharmaceuticals, Ltd. | Device and method for the application of a curable fluid composition to a portion of a bodily organ |
| USD754325S1 (en) | 2013-06-06 | 2016-04-19 | Omrix Biopharmaceuticals Ltd. | Device of a curable fluid composition to a bodily organ |
| IL230151A0 (en) | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing a polymerization inhibitor |
| IL230150A0 (en) | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| IL231230A0 (en) | 2014-02-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Fibrinogen preparation |
| IL231792A0 (en) | 2014-03-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Device and method for the preparation and administration of one-component fibrin glue |
| IL234246A0 (en) | 2014-08-21 | 2014-11-30 | Omrix Biopharmaceuticals Ltd | Stabilized thrombin |
| EP3258945B1 (en) | 2015-02-16 | 2020-10-07 | Nayacure Therapeutics Ltd. | Modified blood clots |
| IL247821A0 (en) | 2016-09-14 | 2017-01-31 | Omrix Biopharmaceuticals Ltd | Adhesive preparations and their use |
| IL249725A0 (en) | 2016-12-22 | 2017-03-30 | Omrix Biopharmaceuticals Ltd | A hemostatic preparation containing an anion exchanger and a calcium salt |
| IL263679A (en) * | 2018-12-12 | 2019-03-31 | Omrix Biopharmaceuticals Ltd | Kits, methods, and ingredients for preventing tissue adhesion |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT359652B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| ATE20824T1 (de) * | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung. |
| US4627879A (en) * | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| ATE111360T1 (de) * | 1988-05-02 | 1994-09-15 | Project Hear | Chirurgisches klebstoffmaterial. |
| FR2650508A1 (fr) * | 1989-08-01 | 1991-02-08 | Fondation Nale Transfusion San | Colle pasteurisee pour reunir des tissus humain ou animal |
-
1991
- 1991-09-27 CZ CS922942A patent/CZ280540B6/cs unknown
- 1991-09-27 WO PCT/EP1991/001850 patent/WO1993005822A1/en active Application Filing
- 1991-09-27 SK SK2942-92A patent/SK294292A3/sk unknown
-
1992
- 1992-09-02 AT AT92114942T patent/ATE200631T1/de active
- 1992-09-02 DE DE69231791T patent/DE69231791T2/de not_active Expired - Lifetime
- 1992-09-02 ES ES92114942T patent/ES2155437T3/es not_active Expired - Lifetime
- 1992-09-09 IL IL10311892A patent/IL103118A/en not_active IP Right Cessation
- 1992-09-22 AU AU25288/92A patent/AU648198B2/en not_active Expired
- 1992-09-24 CA CA002079077A patent/CA2079077C/en not_active Expired - Fee Related
- 1992-09-25 BR BR929203763A patent/BR9203763A/pt not_active Application Discontinuation
- 1992-09-25 HU HU9203070A patent/HUT67051A/hu unknown
- 1992-09-25 ZA ZA927360A patent/ZA927360B/xx unknown
- 1992-09-25 FI FI924306A patent/FI924306A/fi unknown
- 1992-09-25 NO NO19923737A patent/NO316155B1/no not_active IP Right Cessation
- 1992-09-28 JP JP28112592A patent/JP2668762B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-30 HU HU95P/P00739P patent/HU211631A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE200631T1 (de) | 2001-05-15 |
| DE69231791D1 (de) | 2001-05-23 |
| FI924306A (fi) | 1993-03-28 |
| AU2528892A (en) | 1993-04-01 |
| CZ294292A3 (en) | 1994-02-16 |
| SK294292A3 (en) | 1994-06-08 |
| NO923737L (no) | 1993-03-29 |
| BR9203763A (pt) | 1993-04-20 |
| CZ280540B6 (cs) | 1996-02-14 |
| WO1993005822A1 (en) | 1993-04-01 |
| FI924306A0 (fi) | 1992-09-25 |
| HUT67051A (en) | 1995-01-30 |
| CA2079077A1 (en) | 1993-03-28 |
| JPH05194263A (ja) | 1993-08-03 |
| ES2155437T3 (es) | 2001-05-16 |
| IL103118A0 (en) | 1993-02-21 |
| NO923737D0 (no) | 1992-09-25 |
| HU211631A9 (en) | 1995-12-28 |
| HU9203070D0 (en) | 1992-12-28 |
| DE69231791T2 (de) | 2001-11-22 |
| IL103118A (en) | 1996-11-14 |
| AU648198B2 (en) | 1994-04-14 |
| ZA927360B (en) | 1993-05-03 |
| CA2079077C (en) | 1999-11-30 |
| JP2668762B2 (ja) | 1997-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0534178B1 (en) | Improved tissue glue prepared by using cryoprecipitate | |
| NO316155B1 (no) | Forbedret vevslim fremstilt ved anvendelse av kryopresipitat, fremgangsmåtefor fremstilling derav, samt anvendelse av en mengde avproteaseinhibitor | |
| US5260420A (en) | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof | |
| JP4666764B2 (ja) | 血漿から安定で、長期型のトロンビンを調製するための装置および方法、並びにこれにより形成されたトロンビン | |
| Hartman et al. | Autologous whole plasma fibrin gel: intraoperative procurement | |
| JP4860857B2 (ja) | 自己由来トロンビン | |
| CA2201714C (en) | Method for isolation of highly pure von willebrand factor | |
| US5643192A (en) | Autologous fibrin glue and methods for its preparation and use | |
| EP0654078B1 (en) | A thrombin blood fraction for use in a medical procedure | |
| CA2113660C (en) | Process for the obtention of biological adhesive made of concentrated coagulation factors by salting-out | |
| US20050118156A1 (en) | Storage-stable fibrin sealant | |
| Wang et al. | Fibrin sealant reduces perioperative blood loss in total hip replacement | |
| JP2004500026A5 (pt) | ||
| WO1992013495A1 (en) | Fibrinogen based adhesive | |
| CA2728358C (en) | Storage-stable, functionally intact fibrinogen | |
| WO1994022503A1 (en) | Two component fibrin glue | |
| Burnouf et al. | Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue | |
| Kumar et al. | Whole blood thrombin: development of a process for intra-operative production of human thrombin | |
| EP0497929B1 (fr) | Composition pour stabiliser le plasma sanguin en cours de pasteurisation | |
| EP1057490A2 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition | |
| de Lille | llllllllllllllllllllllIlllllwglllllllllIllllllllllllllllllllllllllllllll | |
| CA2367124C (en) | A thrombin blood fraction for use in a medical procedure | |
| Dunn et al. | Topical thrombin preparations and their use in cardiac surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |